Who
Sarah Krepp
Chief Human Resource Officer
Company insider
Files Form 4 as: Chief Human Resource Officer, Liquidia.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $7.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jul 2025
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Jul 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $149K5,245 at $28.48 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —3,178 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,178 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $19K274 at $67.76 | filing |
| 1 Sep 2026filed 3 Sep 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $19K274 at $67.76 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $40K558 at $71.39 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $523K7,306 at $71.52 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $40K558 at $71.39 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $523K7,306 at $71.52 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —3,179 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,179 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,179 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —3,179 | filing |
| 11 Jun 2026filed 15 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $404K5,749 at $70.28 | filing |
| 11 Jun 2026filed 15 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $1.3M19,131 at $70.28 | filing |
| 11 Jun 2026filed 15 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $404K5,749 at $70.28 | filing |
| 11 Jun 2026filed 15 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $1.3M19,131 at $70.28 | filing |
| 1 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $17K276 at $60.87 | filing |
| 1 Jun 2026filed 3 Jun 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $17K276 at $60.87 | filing |
| 13 Apr 2026filed 14 Apr 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $175K4,557 at $38.37 | filing |
News
Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option BuyingLQDA · dailypolitical.com · 14 Oct 2026Insider Selling: Liquidia (NASDAQ:LQDA) General Counsel Sells $389,948.16 in StockLQDA · themarketsdaily.com · 14 Oct 2026Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHLQDA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Sarah Krepp; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.